Drug Database
NI

nilotinib (Danziten)

✓ Approved

Azurity Pharmaceuticals, Inc. · ABL1 · 小分子

什么是 nilotinib?

nilotinib 是一种小分子,由Azurity Pharmaceuticals, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Danziten
公司Azurity Pharmaceuticals, Inc.
药物类别小分子
分子靶点ABL1, BCR, KIT, PDGFRA
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

nilotinib 作用于 4 个分子靶点:

ABL1ABL proto-oncogene 1, non-receptor tyrosine kinase (c-ABL, bcr/abl)
BCRBCR activator of RhoGEF and GTPase (CML, ALL)
KITKIT proto-oncogene, receptor tyrosine kinase (MASTC, CD117)
PDGFRAplatelet derived growth factor receptor alpha (PDGFR-2, CD140A)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

nilotinib 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Chronic myeloid leukaemia✓ Approved

相关研究文献

PubMedThe oncologist2026-11-19

Long-Term Cardiovascular Adverse Events in Patients with Chronic Myelogenous Leukemia Treated with Tyrosine Kinase Inhibitors.

Zureigat Hadil H, Mohamed Ahmed N AN, Govande Sneha S, Zabor Emily C EC et al.

patients with chronic myelogenous leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) are at risk for cardiotoxicity. Risk estimates from clinical trials may be limited by healthier populations and short follow-up durations. we evaluated the incidence of cardiovascular adverse events (CVD-AE) and echocardiographic changes as a secondary outcome in CML patients on TKIs, accounting for cardiovascular risk from prior TKI exposure. CML patients treated with TKIs at Cleveland Clinic (2007-2022) were included. TKIs analyzed were imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib. Data included demographics, comorbidities, treatments, and follow-up. Outcomes were overall survival and major adverse cardiovascular events (MACE): acute coronary syndrome (ACS), heart failure, stroke, peripheral arterial disease, and revascularization. Pleural effusions, pericardial effusions and pulmonary hypertension were assessed. Echocardiograms were collected at baseline. Multivariable Cox regression and generalized linear mixed models were applied. among 357 patients (median age 56; 57% male; 85% White), 518 CVD-AE occurred during median follow-up of 7.2 years. Compared with imatinib, nilotinib was associated with increased ACS (HR 3.5, P = 0.02), dasatinib with heart failure (HR 2.5, P = 0.04), and dasatinib, and asciminib with pleural (HRs 3.5, 5.8; P < 0.05) and pericardial effusions (HR 5.1, 21.6; P < 0.05). Dasatinib was associated with lower venous thrombosis (HR 0.1, P = 0.02). MACE incidence did not differ significantly among TKIs. Among 69 patients with serial echocardiograms, ponatinib decreased left ventricular ejection fraction (β = -5.2, P = 0.008) and bosutinib increased global longitudinal strain (β = 3.0, P = 0.037). Cardiovascular risks differ among TKIs, and therapy duration influences echocardiographic changes.

PMID 43053278
阅读全文 →
PubMedSignal transduction and targeted therapy2026-11-18

Deep single-cell immune- and signaling profiles predict therapy response in chronic myeloid leukemia within hours.

Gullaksen Stein-Erik SE, Brevik Mathias M, Craig Erin E, Hellesøy Monica M et al.

Chronic myeloid leukemia (CML) is effectively treated with small molecule BCR::ABL1 tyrosine kinase inhibitors (TKIs) but as in all cancers, early identification of suboptimal responders and non-responders is a challenge. Through mass cytometry analysis of peripheral blood leukocytes collected on the first day of TKI treatment, we generated high-dimensional single-cell data from de novo chronic phase CML patients enrolled in two multicenter clinical trials (clinicaltrials.gov: NCT01725204 and NCT01061177). In leukocytes, dasatinib and nilotinib inhibited intracellular signaling within 1 or 3 h after first oral dose, respectively, and each TKI had a unique signaling signature reflecting its kinase specificity profile beyond BCR::ABL1. From these data, an immune and signaling profile was constructed for each patient that predicted the treatment response (BCR::ABL1IS, %) during the first 12 months of treatment. The predictive features were drug specific: response to dasatinib was dominated by leukemic burden, neutrophil maturity (pSTAT3 Y705) and immune effector activity (pERK ½ in T- and NK cells), whereas response to nilotinib was driven by the intrinsic signaling states of CD34+CD38lowCD25+ LSC-like cells (cleaved caspase-3, pCRKL Y207 and STAT3 [total and Y705]). These results show that single cell immune and signaling profiles measured within hours of first dose can predict 12-month treatment response, anticipating future optimization of kinase inhibitor treatment within days rather than months.

PMID 43045686
阅读全文 →
PubMedFrontiers in oncology2026-11-13

Role and mechanism of ribosomal protein S3 in tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Sun Zheng Z, Liu Sijin S, Ning Yuxin Y, Dang Jinwen J et al.

Resistance to tyrosine kinase inhibitors (TKIs) remains a major cause of treatment failure in chronic myeloid leukemia (CML). This study investigated the role of ribosomal protein S3 (RPS3) in TKI resistance and its association with NF-κB signaling. Exploratory RNA sequencing and an RNA-binding protein database were used to prioritize a candidate for subsequent clinical expression and functional analyses. RPS3 expression was examined in an independent clinical cohort and resistant cell models. RPS3 knockdown and pharmacological modulation were used to evaluate drug sensitivity, apoptosis, cell cycle distribution, and NF-κB-associated signaling. RPS3 was upregulated in clinical samples from patients with TKI resistance or poor responses and in resistant cell models. Receiver operating characteristic analysis showed that RPS3 expression discriminated between resistant/poor-response patients and good responders in the validation cohort. RPS3 knockdown lowered imatinib and nilotinib IC50 values, with increased apoptosis and G0/G1-phase arrest following TKI exposure. These effects were accompanied by reduced p65 phosphorylation, a lower p65 nuclear/cytoplasmic fluorescence ratio, and decreased MCL-1 and BCL-XL mRNA levels. TNF-α treatment increased TKI tolerance and reduced TKI-induced apoptosis in RPS3-knockdown cells, whereas co-treatment with BAY-11-7082 counteracted these effects. BAY-11-7082 also showed synergistic inhibitory effects with TKIs in resistant cells under the highest single agent model. These findings identify RPS3 as a contributor to TKI resistance in CML cell models and connect its functional effects to NF-κB-associated anti-apoptotic signaling. By integrating clinical expression data with functional and pharmacological analyses, this study supports further investigation of RPS3 as a candidate target for sensitizing resistant CML cells to TKIs.

PMID 43021846
阅读全文 →
PubMedJournal of clinical apheresis2026-11-12

Thrombocytapheresis for Extreme Thrombocytosis: A 20-Year Single-Center Experience With Acute and Chronic Use in Myeloproliferative Neoplasms.

Weli Homayemem K HK, Gorham James D JD, Balogun Rasheed A RA

Thrombocytapheresis is an established adjunctive therapy for rapid platelet cytoreduction in patients with extreme thrombocytosis, particularly in myeloproliferative neoplasms (MPNs), where it is typically used alongside cytoreductive pharmacotherapy. Real-world longitudinal data describing utilization, effectiveness, and safety remain limited. The aim of this study was to evaluate or characterize the indications, utilization patterns, hematologic responses, and safety outcomes of thrombocytapheresis over a 20-year period at a single institution and illustrate key clinical applications through two illustrative cases. We conducted a retrospective 20-year institutional review of thrombocytapheresis, highlighting two illustrative cases. Cases were identified using EPIC SlicerDicer. Patient demographics, indications, laboratory responses, adverse events, access complications, electrolyte abnormalities, and short-term outcomes were extracted and analyzed. Pre- and post-platelet count changes were assessed using paired Wilcoxon testing, with exploratory analyses of other blood cells and descriptive evaluation of safety outcomes. After applying exclusion criteria, 9 patients undergoing 38 thrombocytapheresis procedures were analyzed, with one patient accounting for nearly half of all procedures. Most procedures were performed for MPN-related thrombocytosis. In the broader cohort, platelet counts decreased significantly after the first procedure (median 1511 to 666 × 109/L; p = 0.008), corresponding to a mean reduction of 45% with no significant changes in red cell and white cell counts. Adverse events were uncommon and primarily related to citrate-associated hypocalcemia or vascular access rather than to circuit-related complications. We also report two cases describing thrombocytapheresis use in patients with extreme thrombocytosis (> 2.9 million/μL) in distinct myeloid neoplasms. The first patient was diagnosed with polycythemia vera evolving from essential thrombocythemia and demonstrated relative refractoriness and platelet count rebound despite cytoreductive therapy, followed by rapid platelet decline but poor clinical outcome. The second is a case of chronic myeloid leukemia refractory to multiple tyrosine kinase inhibitors (including dasatinib and nilotinib). The patient demonstrated sustained responsiveness to serial thrombocytapheresis over 2 years. In this cohort, thrombocytapheresis was effective for rapid platelet reduction and demonstrated an acceptable safety profile. Clinical outcomes are largely dictated by underlying disease severity and concurrent cytoreductive therapy, rather than procedural response alone. In selected patients, thrombocytapheresis may serve as an effective bridging therapy while awaiting definitive treatment.

PMID 43014826
阅读全文 →
PubMedSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026-11-12

Development, validation, and pilot-testing of a comprehensive patient-reported EORTC custom questionnaire for monitoring real-world tyrosine kinase toxicity in chronic myeloid leukemia.

Smit Yolba Y, Timmerman Jacolien J, Currie Alexander A, Soltan Hatem H et al.

In chronic myeloid leukemia (CML), treatment choices between tyrosine kinase inhibitors (TKIs) are guided by efficacy and tolerability, yet no instrument adequately captures tolerability from the patient perspective. As a result, TKI choice may not comprehensively take into account the prevalence and severity of what patients' experience. We therefore developed, validated, and pilot-tested a new custom questionnaire to capture real-world patients' experiences, and explored pilot data. A mixed-methods study was conducted, following COREQ and STROBE guidelines. Development started with CML-specific items from existing instruments, followed by semi-structured sessions with purposefully sampled patients, and convenience-sampled professionals, focused on comprehensibility, comprehensiveness, relevance, acceptability, workflow, and graphics. Based on qualitative analyses, items were substituted or added from the EORTC Item library. Psychometric quantitative evaluation assessed filter question validity, redundancy, reliability, measurement error, responsiveness, scale construction, and symptom severity differences in pilot data and meta-analyses. A new EORTC custom questionnaire was developed, covering 50 symptoms. Seven of those symptoms are covered by scales consisting of multiple items, with a Cronbach's alpha ≥ 0.73 for each of those scales. Psychometric properties further showed fair-to-excellent reliability and positive agreement between time points ranging from 45 to 93% in test-retest, while responsiveness was indicated for half of symptoms. Twenty-four generic filter questions are available for computer adaptive testing, an option preferred by 87% of patients. For 23 issues, no existing EORTC item was available; these need to be added later. Pilot data showed that the severity of symptoms, as reported by patients, differed significantly between the three most common TKIs in a third of symptoms. These significant differences ranged from 5 to 30%. The highest difference was for swelling of the eyes or face, which was reported 30% more severe in patients on imatinib, compared to patients on nilotinib, when adjusted for age, gender, years since diagnosis, years on current treatment, and TKI-dosage. We could not adjust for comorbidity or comedication. We developed and validated an EORTC custom questionnaire and workflow to monitor 50 CML patient-reported toxicity symptoms in clinical care. Sexuality problems are excluded from pre-existing instruments, yet pilot data revealed these are prevalent and severe from patients' perspective. One-third of evaluated symptoms varied in severity by type of TKI treatment, independent from age, gender, years since diagnosis, years on current treatment, and TKI-dosage. These findings can tentatively inform shared decision-making, when switching TKIs due to intolerability.

PMID 43018785
阅读全文 →
PubMedJournal of biochemical and molecular toxicology2026-11-11

Targeting TLR2 to Overcome Autophagy-Dependent Chemoresistance in Gastric Cancer: Integrating Molecular Docking, Mechanistic Validation, and Therapeutic Evaluation.

Zheng Kuanheng K, Lei Xinjian X, Lin Bin B, Yang Qianhong Q et al.

Chemoresistance remains a major barrier to effective treatment of gastric cancer (GC), particularly in advanced disease, where cytotoxic chemotherapy often yields limited and transient responses. The present study provides integrated computational and experimental evidence that targeting TLR2 using repurposed small-molecule inhibitors can overcome autophagy-dependent chemoresistance in gastric adenocarcinoma cells. A library comprising 1555 FDA-approved drugs was sourced from the DrugBank database, virtual screening was executed, and two compounds, Nilotinib (DB04868) and Lomitapide (DB08827), achieved affinities ≤ -10 kcal/mol. Chemoresistant GC cells were developed, and experimental assessment was performed using cell proliferation assay, apoptosis assay, real-time PCR, and western blot analysis. Nilotinib and Lomitapide significantly reduced the proliferation but increased the apoptosis of chemoresistant GC cells. Additionally, Nilotinib and lomitapide reduced the mRNA and protein levels of autophagy-related factors, LC3B, Beclin-1, and p62/SQSTM1, and activated transcription factors in chemoresistant GC cells. In conclusion, our results suggest that combining TLR2-targeted agents with standard chemotherapy could be a promising strategy to overcome refractory disease in GC.

PMID 43012433
阅读全文 →

注册免费账户还可查看另外 2986 篇文献

免费注册查看全部文献 →

了解更多nilotinib